AMGN · 8-K · 20261103PR000153

Competition and Pricing Pressure

AMGEN INC · 2026-11-03 · Importance 64 · Surprise 56

Prolia sales declined 45% year over year to $632 million and XGEVA sales declined 47% to $288 million as multiple biosimilars launched globally; lower volume contributed substantially to both declines. XGEVA also had an 11% reduction in net selling price, while Prolia’s decline included lower net selling price and changes to estimated sales deductions. PAVBLU sales rose 41% to $300 million, supported by 71% volume growth but partly offset by an 18% lower net selling price; Enbrel’s net selling price fell 14%, reflecting the impact of U.S. Medicare Part D price setting.